Bullous Pemphigoid Clinical Trials 2023

What are the top hospitals conducting bullous pemphigoid research?

When it comes to advancing the understanding and treatment of bullous pemphigoid, several hospitals across the United States are making significant contributions. In Boca Raton, Investigator Site 2 (US0010087) is currently conducting one active clinical trial for this rare autoimmune disorder. This marks their first recorded bullous pemphigoid trial in 2022, showcasing their commitment to pushing the boundaries of medical research. Similarly, Investigator Site 1 (US0010017) in Miami is also actively involved in a bullous pemphigoid trial, further emphasizing the nationwide efforts towards better managing this condition.

Heading northward to Morgantown, we find Investigator Site 3 (US0010151), where another ongoing clinical trial focusing on bullous pemphigoid is taking place. The hospital's dedication to studying this disease since its first recorded trial in 2022 demonstrates their determination to improve patient outcomes and quality of life. Moving westwards brings us to Fairborn's Investigator Site 4 (US0010137), which mirrors its counterparts by conducting an active bullous pemphigoid trial alongside a rich history of contributing to research within this field.

Finally, situated on the West Coast is Fountain Valley's Investigator Site 6 (US0010138). Here too they have embarked upon an endeavor exploring potential treatments for bullous pemphigoid through an ongoing clinical study. Their recent entry into conducting trials for this condition highlights how collaboration between multiple sites across diverse locations can lead us closer toward breakthroughs and advancements that benefit patients worldwide.

These various investigator sites working diligently on understanding and treating bullous pemphigoid demonstrate our collective commitment towards combating rare diseases like these with comprehensive research initiatives aiming at improved diagnostics and therapies - ultimately paving a path towards alleviating suffering faced by affected individuals globally.

Which are the best cities for bullous pemphigoid clinical trials?

In the realm of bullous pemphigoid clinical trials, several cities emerge as key players in advancing research and treatment options. Miami, Florida takes the lead with 2 active trials exploring efgartigimod PH20 SC, dupilumab, and other potential interventions. Clearwater, Florida also boasts 2 ongoing studies focusing on efgartigimod PH20 SC and related treatments. Similarly, Ann Arbor, Michigan joins this group with 2 active trials investigating efgartigimod PH20 SC, dupilumab, and other potential therapies. Lastly, Phoenix Arizona and Saint Louis Missouri each contribute to scientific advancement with their respective 2 active trials studying efgartigimod PH20 SC alongside additional interventions like Benralizumab. These cities offer individuals living with bullous pemphigoid access to cutting-edge clinical research that may shape future treatment approaches for this challenging condition.

Which are the top treatments for bullous pemphigoid being explored in clinical trials?

Exciting developments are underway in the world of bullous pemphigoid research, with several top treatments currently being explored in clinical trials. Leading the pack is efgartigimod PH20 SC, which is showing promise in one active trial and has a total of two all-time trials dedicated to bullous pemphigoid since its listing in 2022. Benralizumab follows closely behind, with one active trial and one all-time trial for this condition since 2021. Another notable contender is dupilumab, making waves with one active and one all-time trial since its introduction in 2020. Finally, there's an intriguing combination therapy involving Rituximab and Omalizumab that shows potential; it's currently being investigated in a single active clinical trial after being listed just last year (2023). These ongoing studies offer hope for improved treatment options for individuals living with bullous pemphigoid.

What are the most recent clinical trials for bullous pemphigoid?

Exciting advancements are being made in the field of bullous pemphigoid, with recent clinical trials offering promising prospects for treatment. One notable trial involves combining Rituximab and Omalizumab as a potential therapy for bullous pemphigoid. This Phase 3 study, which became available on 5/25/2023, aims to evaluate the efficacy and safety of this combination approach. Another significant trial investigated the use of efgartigimod PH20 SC in patients with bullous pemphigoid. This Phase 2 and Phase 3 study commenced on 6/9/2022, aiming to assess the effectiveness of efgartigimod PH20 SC as a therapeutic option. These innovative trials bring hope to those affected by bullous pemphigoid by exploring new treatment possibilities that may improve patient outcomes.

What bullous pemphigoid clinical trials were recently completed?

In December 2020, the University of California, San Francisco concluded a significant clinical trial for bullous pemphigoid. The study focused on evaluating the efficacy of dexamethasone 0.5mg/5ml solution in Mucolox™ as a potential treatment option for this dermatological condition. This groundbreaking research offers valuable insights into improving therapeutic approaches against bullous pemphigoid and paves the way for enhanced patient care in the future.